title: Combination of enzastaurin and pemetrexed inhibits cell growth and induces apoptosis of chemoresistant ovarian cancer cells regulating extracellular signal-regulated kinase 1/2 phosphorylation.
abstract: New strategies in the therapy for malignant diseases depend on a targeted influence on signal transduction pathways that regulate proliferation, cell growth, differentiation, and apoptosis by the activation of serine/threonine kinases. Enzastaurin (LY317615.HCl), a selective inhibitor of protein kinase Cbeta (PKCbeta), is one of these new drugs and causes inhibition of proliferation and induction of apoptosis. Pemetrexed, a multitarget inhibitor of folate pathways, is broadly active in a wide variety of solid tumors. Therefore, the effect of enzastaurin and the combination treatment with pemetrexed was analyzed when applied to the drug-sensitive ovarian cancer cell line HEY and various subclones with drug resistance against cisplatin, etoposide, docetaxel, and paclitaxel, as well as pemetrexed, and gemcitabine. In these novel chemoresistant subclones, the expression of the enzastaurin targets PKCbetaII and glycogen synthase kinase 3beta (GSK3beta) was analyzed. Exposition to enzastaurin showed various inhibitory effects on phosphorylated forms of GSK3beta and the mitogen-activated protein kinase extracellular signal-regulated kinase 1/2. Cell proliferation experiments identified the cell line-specific half-maximal inhibitory concentration values of enzastaurin and a synergistic inhibitory effect by cotreatment with the antifolate pemetrexed. Induction of apoptosis by enzastaurin treatment was investigated by Cell Death Detection ELISA and immunoblot analyses. Simultaneous treatment with pemetrexed resulted in an enhanced inhibition of proliferation and induction of apoptosis even in partial enzastaurin-resistant cells. Therefore, the combinational effect of enzastaurin and pemetrexed can have promise in clinical application to overcome the fast-growing development of resistance to chemotherapy in ovarian cancer.
authors.affiliation: Department of Gynecology and Obstetrics, University Hospital Schleswig-Holstein, Kiel, Germany.
authors.forename: Karen
authors.initials: K
authors.lastname: Bräutigam
authors.forename: Dirk Olaf
authors.initials: DO
authors.lastname: Bauerschlag
authors.forename: Marion Tina
authors.initials: MT
authors.lastname: Weigel
authors.forename: Julia
authors.initials: J
authors.lastname: Biernath-Wüpping
authors.forename: Thomas
authors.initials: T
authors.lastname: Bauknecht
authors.forename: Norbert
authors.initials: N
authors.lastname: Arnold
authors.forename: Nicolai
authors.initials: N
authors.lastname: Maass
authors.forename: Ivo
authors.initials: I
authors.lastname: Meinhold-Heerlein
references.citation: Cancer Chemother Pharmacol. 2004 Feb;53(2):133-40
references.pmid: 14593497
references.citation: Invest New Drugs. 2007 Jun;25(3):205-10
references.pmid: 17347872
references.citation: J Biol Chem. 2004 Mar 5;279(10):9233-47
references.pmid: 14670956
references.citation: FEBS Lett. 2001 Nov 9;508(1):126-30
references.pmid: 11707282
references.citation: J Clin Oncol. 2006 Sep 1;24(25):4092-9
references.pmid: 16943527
references.citation: Int Rev Cytol. 2006;251:131-58
references.pmid: 16939779
references.citation: Adv Enzyme Regul. 2005;45:229-55
references.pmid: 16143373
references.citation: Oncogene. 2004 Dec 2;23(56):9062-9
references.pmid: 15489897
references.citation: J Biol Chem. 1992 Aug 25;267(24):16878-82
references.pmid: 1324914
references.citation: Br J Cancer. 2008 Sep 2;99(5):750-9
references.pmid: 18728666
references.citation: J Clin Invest. 2004 Jun;113(11):1615-23
references.pmid: 15173888
references.citation: Cell Signal. 2004 Aug;16(8):951-7
references.pmid: 15157674
references.citation: Pharmacol Res. 2007 Jun;55(6):477-86
references.pmid: 17548205
references.citation: Int J Clin Pharmacol Ther. 2005 Dec;43(12):603-4
references.pmid: 16372535
references.citation: Nature. 1995 Dec 21-28;378(6559):785-9
references.pmid: 8524413
references.citation: Expert Opin Investig Drugs. 2001 Dec;10(12):2117-40
references.pmid: 11772309
references.citation: Nat Rev Cancer. 2007 Apr;7(4):281-94
references.pmid: 17384583
references.citation: Ann Oncol. 2006 May;17 Suppl 5:v29-32
references.pmid: 16807459
references.citation: Cancer Sci. 2008 Mar;99(3):486-96
references.pmid: 18167130
references.citation: Mol Cell Biol. 2002 Apr;22(7):2099-110
references.pmid: 11884598
references.citation: FASEB J. 1995 Apr;9(7):484-96
references.pmid: 7737456
references.citation: J Clin Invest. 1996 Nov 1;98(9):2018-26
references.pmid: 8903320
references.citation: Oncology (Williston Park). 2004 Nov;18(13 Suppl 8):63-5
references.pmid: 15655940
references.citation: Br J Pharmacol. 1999 Mar;126(6):1419-25
references.pmid: 10217536
references.citation: J Clin Oncol. 2000 Sep;18(17):3084-92
references.pmid: 10963636
references.citation: FEBS Lett. 2000 Nov 10;484(3):217-23
references.pmid: 11078882
references.citation: Mol Cancer Ther. 2006 Jul;5(7):1783-9
references.pmid: 16891464
references.citation: Cancer. 2007 Feb 15;109(4):685-91
references.pmid: 17219441
references.citation: Clin Cancer Res. 2004 Jun 15;10(12 Pt 2):4276s-4280s
references.pmid: 15217974
references.citation: Cancer Res. 2005 Aug 15;65(16):7462-9
references.pmid: 16103100
references.citation: Mol Cancer Ther. 2007 Feb;6(2):404-17
references.pmid: 17308042
references.citation: BMC Neurosci. 2005 Feb 02;6:8
references.pmid: 15689238
references.citation: Cancer Res. 2008 Mar 15;68(6):1916-26
references.pmid: 18339873
references.citation: Cancer Lett. 2008 Sep 8;268(1):46-55
references.pmid: 18462865
references.citation: CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
references.pmid: 18287387
references.citation: J Reprod Med. 2001 Jul;46(7):621-9; discussion 629-30
references.pmid: 11499181
references.citation: Mol Pharmacol. 2005 Jul;68(1):110-8
references.pmid: 15795320
references.citation: J Biol Chem. 2004 Nov 12;279(46):47720-5
references.pmid: 15364915
references.citation: J Endocrinol. 2006 Jan;188(1):79-89
references.pmid: 16394177
references.citation: Mol Cancer Ther. 2008 Jun;7(6):1698-707
references.pmid: 18566241
references.citation: Invest New Drugs. 2008 Jun;26(3):215-22
references.pmid: 18000644
references.citation: J Neurochem. 2008 Sep;106(6):2436-48
references.pmid: 18662322
references.citation: Blood. 2007 Feb 15;109(4):1669-77
references.pmid: 17023575
references.citation: J Invest Dermatol. 2006 Jul;126(7):1641-7
references.pmid: 16645590
references.citation: J Biol Chem. 1995 Jan 20;270(3):987-90
references.pmid: 7836418
references.citation: Biochem J. 1994 Nov 1;303 ( Pt 3):701-4
references.pmid: 7980435
references.citation: J Biol Chem. 2004 May 21;279(21):22118-23
references.pmid: 15037605
references.citation: Bioorg Med Chem Lett. 2003 Jun 2;13(11):1857-9
references.pmid: 12749884